Hydroxychloroquine combination risky for cancer patients with COVID-19: study

Cancer patients with COVID-19 who were treated with a drug combination promoted by U.S. President Donald Trump to counter the coronavirus were three times more likely to die within 30 days than those who got either drug alone, U.S. researchers reported on Thursday. 

The preliminary results suggest doctors may want to refrain from prescribing the decades-old malaria treatment hydroxychloroquine with the antibiotic azithromycin for these patients until more study is done, researchers said. 

Click here for more